Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers

Background The programmed cell death protein-1 (PD-1)/programmed death receptor ligand 1 (PD-L1) axis critically facilitates cancer cells immune evasion. Antibody therapeutics targeting the PD-1/PD-L1 axis have shown remarkable efficacy in various tumors. Immuno-positron emission tomography (ImmunoP...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cheng Wang, Dong Xu, Jianjun Liu, Gang Huang, Haitao Zhao, You Zhang, Jonathan W Engle, Min Cao, Yanfei Wu, Sara Malih, Erpeng Yang, Muhsin H Younis, Wilson Lin, Qiufang Liu, Mohammad J Rasaee, Yihui Guan, Weibo Cai, Fang Xie, Weijun Wei
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	BMJ Publishing Group 2024-04-01
Colección:	Journal for ImmunoTherapy of Cancer
Acceso en línea:	https://jitc.bmj.com/content/12/4/e008794.full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers

Ejemplares similares